Comparative Pharmacology
Head-to-head clinical analysis: CELONTIN versus TOPAMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELONTIN versus TOPAMAX.
CELONTIN vs TOPAMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases levels of gamma-aminobutyric acid (GABA) in the central nervous system, possibly by inhibiting GABA transaminase or enhancing GABA release; also reduces calcium influx into neurons, stabilizing neuronal membranes.
Antiepileptic; modulates voltage-gated sodium channels, enhances GABA-A activity, antagonizes AMPA/kainate glutamate receptors, weakly inhibits carbonic anhydrase.
300 mg orally three times daily, increased by 300 mg every 3-4 days as tolerated; usual maintenance dose 900-2400 mg/day in divided doses.
Initial dose 25 mg orally twice daily; titrate by 25-50 mg weekly to effective dose; usual maintenance dose 200-400 mg/day divided twice daily; maximum 1600 mg/day.
None Documented
None Documented
Terminal elimination half-life: 40-60 hours in adults, 30-45 hours in children; prolonged liver disease or renal impairment may increase half-life.
Terminal elimination half-life is 21 hours (range 18-23 hours). Linear pharmacokinetics. Half-life is prolonged in renal impairment (CrCl <70 mL/min: ~35 hours).
Renal: approximately 40-60% as unchanged drug; hepatic metabolism accounts for the remainder, with metabolites excreted renally.
Renal: ~70% (unchanged drug); remainder as metabolites. Biliary/fecal: minimal (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant